NEOS Investment Management LLC Has $4.29 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

NEOS Investment Management LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,008 shares of the medical research company’s stock after purchasing an additional 1,282 shares during the period. NEOS Investment Management LLC’s holdings in Edwards Lifesciences were worth $4,294,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Sava Infond d.o.o. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $370,000. WINTON GROUP Ltd acquired a new position in Edwards Lifesciences during the fourth quarter worth $3,230,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Edwards Lifesciences by 6.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 951,514 shares of the medical research company’s stock worth $70,326,000 after buying an additional 58,352 shares during the last quarter. Korea Investment CORP raised its position in Edwards Lifesciences by 46.5% during the fourth quarter. Korea Investment CORP now owns 470,650 shares of the medical research company’s stock worth $34,842,000 after acquiring an additional 149,315 shares in the last quarter. Finally, Banco BTG Pactual S.A. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at $508,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,553 shares of company stock worth $4,513,064. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $71.17 on Friday. The company’s 50-day moving average price is $71.47 and its two-hundred day moving average price is $70.46. The firm has a market cap of $41.84 billion, a P/E ratio of 10.21, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on EW shares. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Piper Sandler upped their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Evercore ISI decreased their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.